Zhongxin Finance, February 11. On the 11th, Chen Jinfu, deputy director of the National Medical Security Administration, said at the State Council's regular policy briefing on the progress of deepening the reform of centralized procurement of drugs and high-value medical consumables. Judging from the cumulative results of the three-year reform, The state organized centralized procurement to save more than 260 billion yuan.
According to Chen Jinfu, since 2018, the National Medical Insurance Administration, together with relevant state departments, has promoted the reform of the procurement of medicines and high-value medical consumables by volume. After three years of hard work, six batches of medicines have been carried out so far. Purchasing, a total of 234 kinds of drugs were purchased, and the amount involved accounted for 30% of the total annual drug purchases of public medical institutions.
Judging from the results achieved, the centralized procurement rules have been continuously optimized, the quality supervision has become more rigorous, the supply guarantee has become more stable, and the use policy has become more complete.
First, the price has returned to a reasonable level, and the masses have benefited significantly.
The first six batches of centralized procurement of medicines dropped by an average of 53%, heart stents by an average of 93%, and artificial hip joints and knee joints by an average of 82%.
The overall drug price level shows a trend of stability and decline. According to the drug price monitoring data carried out by the Medical Insurance Bureau, the overall drug price level will continue to decline in 2019 and 2021, with an average annual rate of about 7%.
Second, the quality of drugs and consumables for clinical use has been steadily improved, and the demand for clinical services has been fully released.
From a statistical point of view, among the varieties of centralized procurement, the share of people using original research drugs and drugs that have passed the consistency evaluation of quality and efficacy has increased from 50% before centralized procurement to more than 90%.
Taking heart stents as an example, 1/3 of the stent products used to be stainless steel, but now they are basically eliminated, and the utilization rate of the selected chrome alloy has reached 95%.
Then there is the imatinib in "I'm not the God of Medicine". After the centralized collection, its usage has increased to 35%, so that patients who need treatment have been fully guaranteed.
The third is to promote the formation of a new pattern of industry development driven by fair competition, quality assurance and innovation.
Through open, transparent, fair and just competition, centralized procurement has gradually improved the market-oriented price formation mechanism in the pharmaceutical field, guided enterprises to strengthen quality and cost control, actively carry out product research and development and consistency evaluation, and through innovation-driven and quality assurance, Make the pharmaceutical industry enter the track of high-quality development.
The fourth is to promote the "three medical linkages".
Through intensive medical insurance fund purchases, including medical insurance prepayment, a series of measures have effectively promoted the internal management of medical institutions and the high-quality development of public medical institutions.
(Finish)